- Mithra grants its first exclusive license for its vaginal contraception ring, Myring, to Mayne Pharma (ASX: MYX), the second-largest supplier of oral contraceptives in the US market, covering commercialization in the United States
- As part of the agreement, Mayne Pharma will pay milestones of at least EUR 10.0m following approval by the US FDA
- Mithra will produce Myring for Mayne Pharma at its Research, Development and Manufacturing facility (Mithra CDMO)
Liège, Belgium 28 February 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is pleased to announce an exclusive long-term license and supply agreement that extends beyond 10 years with Mayne Pharma, a leading specialty pharmaceutical company, for the commercialization in the United States of Myring, Mithra’s combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). Mayne Pharma is the second largest supplier of oral contraceptive products in the US market.